# Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients

> **NCT02515331** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Patients, Resistant Hypertension

## Interventions

- **DRUG:** LHW090
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02515331
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-04
- **Primary completion:** 2017-08-17
- **Final completion:** 2017-08-17
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02515331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02515331, "Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02515331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*